Welcome to our dedicated page for Enliven Therapeutics news (Ticker: ELVN), a resource for investors and traders seeking the latest updates and insights on Enliven Therapeutics stock.
Enliven Therapeutics reports clinical-stage biopharmaceutical developments for a small-molecule oncology pipeline led by ELVN-001, a kinase inhibitor designed to target the BCR::ABL gene fusion in chronic myeloid leukemia. News commonly covers ENABLE clinical-trial updates, CML data presentations, regulatory-development topics, quarterly financial results, and preparation for later-stage development.
Company updates also include leadership and board changes, Nasdaq inducement grants, investor-conference participation, and descriptions of Enliven's precision oncology discovery process built around clinically validated biological targets and differentiated chemistry.
Enliven Therapeutics, a clinical-stage biopharmaceutical company, announced its participation in the Jefferies London Healthcare Conference on November 19, 2024, at 9:30 a.m. GMT. The company's management will engage in a fireside chat, which will be webcast live. Interested parties can access the webcast via the investor relations section of Enliven's website. The webcast will remain available for 90 days post-event.
Enliven Therapeutics (Nasdaq: ELVN) has announced details for the presentation of updated ELVN-001 Phase 1a data at the ESH-iCMLf 26th Annual John Goldman Conference on CML. The event will take place from September 27-29 in Prague, Czech Republic. ELVN-001 is a potent, highly selective, potentially best-in-class small molecule kinase inhibitor targeting the BCR-ABL gene fusion in chronic myeloid leukemia (CML) patients.
The oral presentation, titled "Preliminary safety and efficacy of ELVN-001, a selective active site inhibitor of BCR::ABL1 in CML," will be delivered by Dr. Fabian Lang from Goethe University Hospital on September 28, 2024, at 3:35 p.m. CEST. The presentation will be part of Scientific Session 5: New drugs and combinations. Enliven will make the presentation available on their website after the conference.
Enliven Therapeutics (Nasdaq: ELVN) reported Q2 2024 financial results and provided a business update. Key highlights include:
1. Dosing of first patients in Phase 1b arm for ELVN-001 in CML and Phase 1a trial for ELVN-002 in HER2+ MBC and CRC.
2. Strong financial position with $312.4 million in cash, providing runway into late 2026.
3. R&D expenses increased to $18.8 million in Q2 2024 from $15.2 million in Q2 2023.
4. Net loss widened to $20.0 million in Q2 2024 from $16.7 million in Q2 2023.
5. Upcoming presentation of updated ELVN-001 Phase 1a data at ESH-iCMLf Conference in September 2024.
Enliven Therapeutics (Nasdaq: ELVN), a clinical-stage precision oncology company, has announced its participation in two investor conferences in June 2024. The company will present at the Jefferies Global Healthcare Conference on June 5 at 8:30 a.m. ET and the Goldman Sachs Annual Global Healthcare Conference on June 10 at 3:20 p.m. ET. Both events will feature fireside chats with Enliven's management. The sessions will be webcast live and available on the company's investor relations website, with archives accessible for 30 days post-event.
Enliven Therapeutics announced positive results from its Phase 1 trial of ELVN-001 for chronic myeloid leukemia, showing a 44% major molecular response (MMR) rate by 12 weeks. The company has $321 million in cash, extending its runway to late 2026. A $90 million PIPE financing and board appointment of Lori Kunkel were highlighted. Enliven also advanced its ELVN-002 trial for HER2+ cancers, with the first site activated and patient dosing expected in Q2 2024. Financial results showed increased R&D and G&A expenses, leading to a net loss of $22.7 million for Q1 2024, compared to $14.7 million in Q1 2023.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.